Trials / Completed
CompletedNCT03903211
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjectives With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Jae Seung Kim · Academic / Other
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of \[18F\]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and subjects with mild cognitive impairment and Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]PI-2620 | Imaging for evaluating the accumulation of abnormal tau protein in the brain |
Timeline
- Start date
- 2019-04-09
- Primary completion
- 2021-02-28
- Completion
- 2021-02-28
- First posted
- 2019-04-04
- Last updated
- 2023-09-06
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03903211. Inclusion in this directory is not an endorsement.